Navigation Links
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
Date:2/17/2009

es against the NA and M1 proteins.

"Strong HAI titers combined with a high yielding manufacturing process presents a promising approach to creating an unadjucanted H%N1 vaccine," said Rahul Singhvi, CEO. Although the safety data are still blinded, there have been no serious adverse events reported. An independent, external Data and Safety Monitoring Board reviewed the safety data early in the study, including data among subjects who had received two injections of the 90 mcg dose, and fully supported study continuation.

VLPs are recombinant structures that mimic the size and shape of the virus but lack genetic material and are therefore incapable of replication. Because they resemble actual infectious particles, presenting proteins in the same conformation as the wild-type virus, they are able to induce a potent immune response. The HA and NA are included to induce neutralizing antibody responses to prevent infection and spread of the virus down the respiratory tract into the lungs, whereas the M1 may induce cell-mediated immune responses that provide protection against drifted (i.e., mutated) strains.

Addressing the Gaps in the System

"These data, coupled with the strong neutralizing antibody titer data from this study disclosed last year, demonstrate that the Novavax recombinant VLP vaccine is a valid and potent approach against pandemic influenza. This vaccine and our innovative manufacturing approach have the potential to address an unmet need in pandemic influenza preparedness efforts being planned by health authorities around the world," said Dr. Rahul Singhvi, President and CEO of Novavax.

Novavax's manufacturing process makes it possible to potentially produce and distribute a vaccine matched to a pandemic strain in time to interrupt and/or halt a pandemic. Novavax's influenza VLPs are produced in insect cell culture, utilizing a manufacturing process that co
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
4. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
5. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
6. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014 /PRNewswire/ ... cell-free molecular diagnostics, announced today that Eli ... Sloan Kettering Cancer Center (MSK), presented clinical data ... Trovagene,s precision cancer monitoring platform for the determination ... from a liquid biopsy.  The results were presented ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... published today in the Journal of the American ... 50 years with moderate or severe chronic knee pain, ... the University of Melbourne randomly assigned 282 patients (50 ... acupuncture or sham or pretend laser treatment. , ... acupuncturists blinded to laser and sham (inactive) laser acupuncture. ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... ... product development. , ... Toronto, ON (Vocus) March 29, 2010 -- Therapure Biopharma Inc. today announced a fill/finish ... Under the terms of the agreement, Therapure will provide custom fill/finish services for a ...
... ... nonprofit organization that engages hundreds of thousands of students into humanitarian ... collaborative management of tasks and workflow. Absolute’s Chief Operating Officer reports ... operations transparency, thanks to Wrike’s unique project collaboration features. , ...
... enrolled in therapeutic clinical research trials shows that they don,t ... participation, nor do they feel they are genuinely involved in ... Yoram Unguru, M.D., an associate faculty member at the Johns ... 29 in the journal Pediatrics . While an ...
... combination destroys precancerous colon polyps with no effect on normal ... cancer, a team of scientists at The University of Texas ... edition of the journal Nature . The regimen, ... cancer tissue in the lab, appears to address a problem ...
... rats, the more fattening foods they ate, the more they wanted ... they,d like to eat less but feel almost powerless to stop ... too true. , The theory stems from a study in rats. ... of bacon, pound cake, candy bars and other junk food, the ...
... Unethical job ... wage jobs in Canada. Sometimes these carers do not even have a job when they ... one Vancouver-based business owner says problems could persist. , ... (PRWEB) March 28, 2010 -- New federal legislation coming into force ...
Cached Medicine News:Health News:Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc. 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 3Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 2Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 3Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 2Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 3Health News:Junk Food 'Addiction' May Be Real 2Health News:Junk Food 'Addiction' May Be Real 3Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 2Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: